Corporate digest
Lonza Group
CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange, said it had entered into a binding contractual commitment for the acquisition, but did not disclose the purchase price.
It will use the facility to manufacture drug products for Novartis, as well as to provide production capacity for its additional customers.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Luxury group Richemont reports slowdown in Q4 sales, appoints new CEO
Vietnam forfeits billions of US dollars in foreign aid amid anti-graft freeze
Asia: Stocks mixed after Wall Street, Europe retreat from records
Mapletree closes second Japan logistics development fund, expects 110 billion yen AUM
Dolce & Gabbana metaverse fashion offering leaves shopper fuming
Microsoft offers cloud customers AMD alternative to Nvidia AI processors